دورية أكاديمية
Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies.
| العنوان: | Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies. |
|---|---|
| المؤلفون: | Pedersen-Bjergaard, U, Alsifri, S, Aronson, R, Berković, MC, Galstyan, G, Gydesen, H, Lekdorf, JB, Ludvik, B, Moberg, E, Ramachandran, A, Khunti, K |
| بيانات النشر: | Wiley |
| سنة النشر: | 2019 |
| المجموعة: | University of Leicester: Leicester Research Archive (LRA) |
| مصطلحات موضوعية: | hypoglycaemia, insulin therapy, observational study, systematic review, type 1 diabetes, type 2 diabetes |
| الوصف: | Additional supporting information may be found online in the Supporting Information section at the end of the article. ; AIMS: Optimal diabetes care requires clear understanding of the incidence of hypoglycaemia in real-world clinical practice. Current data on hypoglycaemia are generally limited to those reported from randomised controlled clinical trials. The Hypoglycaemia Assessment Tool (HAT) study, a non-interventional real-world study of hypoglycaemia, assessed hypoglycaemia in 27,585 people across 24 countries. The present study compared the incidence of hypoglycaemia from the HAT study with other similarly designed, large, real-world studies. MATERIALS AND METHODS: A literature search of PubMed (1995-2017) for population-based studies of insulin-treated patients with type 1 or type 2 diabetes (T1D, T2D), excluding clinical trials and reviews, identified comparable population-based studies reporting the incidence of hypoglycaemia. RESULTS: The 24 comparative studies, including >24,000 participants with T1D and >160,000 participants with T2D, varied in design, size, inclusion criteria, definitions of hypoglycaemia and method for recording hypoglycaemia. Reported rates (events/per patient-year [PPY]) of hypoglycaemia were higher in patients with T1D than in those with T2D (overall T1D 21.8-73.3, T2D 1.3-37.7; mild/non-severe T1D 29.0-126.7, T2D 1.3-41.5; severe T1D 0.7-5.8, T2D 0.0-2.5; nocturnal T1D 2.6-11.3, T2D 0.38-9.7), and were similar to the ranges found in the HAT study. CONCLUSIONS: The HAT data on hypoglycaemia incidence were comparable with those from other real-world studies and indicate a high incidence of hypoglycaemia among insulin-treated patients. Differences in rates between studies are mostly explained by differences in patient populations and study methodology. The goal of reducing hypoglycaemia should be a target for continued educational and evidence-based pharmacological interventions. ; The authors thank Watermeadow Medical, funded by Novo Nordisk, for medical writing and ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1463-1326 |
| العلاقة: | https://www.ncbi.nlm.nih.gov/pubmed/30456887Test; Diabetes, Obesity and Metabolism, 2018, 21(4), pp. 844-853; http://hdl.handle.net/2381/44258Test |
| DOI: | 10.1111/dom.13588 |
| الإتاحة: | https://doi.org/10.1111/dom.13588Test http://hdl.handle.net/2381/44258Test |
| حقوق: | Copyright © the authors, 2018. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-commercial License (https://creativecommons.org/licenses/by-nc/4.0Test/), which permits unrestricted use, distribution, and reproduction in any medium non-commercially, provided the original author and source are credited. |
| رقم الانضمام: | edsbas.ECF19C22 |
| قاعدة البيانات: | BASE |
| تدمد: | 14631326 |
|---|---|
| DOI: | 10.1111/dom.13588 |